NASDAQ:BPTH Bio-Path (BPTH) Stock Price, News & Analysis → Exposed: 10 CENT Crypto to Explode April 20th? (From True Market Insiders) (Ad) Free BPTH Stock Alerts $2.68 -0.23 (-7.89%) (As of 04/23/2024 ET) Add Compare Share Share Today's Range$2.60▼$2.8450-Day Range$2.69▼$9.1852-Week Range$2.60▼$44.80Volume317,957 shsAverage Volume1.15 million shsMarket Capitalization$1.83 millionP/E RatioN/ADividend YieldN/APrice Target$40.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainSEC FilingsShort InterestSocial Media Get Bio-Path alerts: Email Address Bio-Path MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside1,389.8% Upside$40.00 Price TargetShort InterestBearish8.97% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.13Based on 16 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($18.71) to ($18.41) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.36 out of 5 stars 3.5 Analyst's Opinion Consensus RatingBio-Path has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageBio-Path has only been the subject of 1 research reports in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted8.97% of the float of Bio-Path has been sold short.Short Interest Ratio / Days to CoverBio-Path has a short interest ratio ("days to cover") of 2.7, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Bio-Path has recently increased by 6.31%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldBio-Path does not currently pay a dividend.Dividend GrowthBio-Path does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for BPTH. Previous Next 2.3 News and Social Media Coverage News SentimentBio-Path has a news sentiment score of 0.13. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.46 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 16 news articles for Bio-Path this week, compared to 1 article on an average week.Search Interest15 people have searched for BPTH on MarketBeat in the last 30 days. This is an increase of 400% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added Bio-Path to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Bio-Path insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 3.05% of the stock of Bio-Path is held by insiders.Percentage Held by InstitutionsOnly 5.74% of the stock of Bio-Path is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Bio-Path are expected to grow in the coming year, from ($18.71) to ($18.41) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Bio-Path is -0.07, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Bio-Path is -0.07, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioBio-Path has a P/B Ratio of 3.78. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad True Market InsidersExposed: 10 CENT Crypto to Explode April 20th?The man who bought Bitcoin and Ethereum in 2017… and has spotted 44 different coins that have returned over 100%... Is now exposing a 10-cent coin that just partnered with Amazon…Click For My #1 FREE Crypto for 2024 About Bio-Path Stock (NASDAQ:BPTH)Bio-Path Holdings, Inc. operates as a clinical and preclinical stage oncology focused RNAi nano particle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction. Its lead drug candidate is prexigebersen, which is in Phase II clinical trials for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome. It is also developing Liposomal Bcl-2 (BP1002) for the treatment of refractory/relapsed lymphoma and chronic lymphocytic leukemia; Liposomal STAT3 (BP1003) for the treatment of pancreatic cancer, non-small cell lung cancer, and AML; and BP1001-A for the treatment of solid tumors. Bio-Path Holdings, Inc. was founded in 2007 and is based in Bellaire, Texas.Read More BPTH Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart BPTH Stock News HeadlinesApril 24, 2024 | americanbankingnews.comBio-Path (NASDAQ:BPTH) Coverage Initiated by Analysts at StockNews.comApril 20, 2024 | americanbankingnews.comBio-Path (NASDAQ:BPTH) Rating Reiterated by Roth MkmApril 24, 2024 | True Market Insiders (Ad)Exposed: 10 CENT Crypto to Explode April 20th?The man who bought Bitcoin and Ethereum in 2017… and has spotted 44 different coins that have returned over 100%... Is now exposing a 10-cent coin that just partnered with Amazon…April 19, 2024 | globenewswire.comBio-Path Holdings, Inc. Announces Closing of $1.2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesApril 18, 2024 | msn.comCrude Oil Edges Lower; Bio-Path Holdings Shares Spike HigherApril 18, 2024 | msn.comWhy Bio-Path Stock Is SoaringApril 18, 2024 | globenewswire.comBio-Path Holdings, Inc. Announces $1.2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesApril 18, 2024 | investorplace.comWhy Is Bio-Path (BPTH) Stock Up 89% Today?April 24, 2024 | True Market Insiders (Ad)Exposed: 10 CENT Crypto to Explode April 20th?The man who bought Bitcoin and Ethereum in 2017… and has spotted 44 different coins that have returned over 100%... Is now exposing a 10-cent coin that just partnered with Amazon…April 18, 2024 | globenewswire.comBio-Path Holdings Announces Successful Completion of Higher Dose Second Cohort in Phase 1/1b Clinical Trial of BP1002 in Refractory/Relapsed Acute Myeloid Leukemia (AML) PatientsApril 17, 2024 | uk.investing.comBio-Path expands patent portfolio in multiple countriesApril 17, 2024 | finanznachrichten.deBio-Path Holdings, Inc.: Bio-Path Holdings Expands Global Patent PortfolioApril 17, 2024 | americanbankingnews.comBio-Path Holdings, Inc. (NASDAQ:BPTH) Short Interest UpdateApril 15, 2024 | baystreet.caBioPath Hikes on International PatentsApril 15, 2024 | globenewswire.comBio-Path Holdings Expands Global Patent PortfolioApril 13, 2024 | morningstar.comBio-Path Holdings Inc BPTHApril 5, 2024 | msn.comDiscovery of a fundamental biological mechanism opens path for novel therapiesApril 4, 2024 | msn.comBio-Path Holdings shares sink 6% after deal for at-the-market offeringApril 2, 2024 | globenewswire.comBio-Path Holdings Provides 2024 Clinical and Operational UpdateMarch 26, 2024 | msn.comBharat Biotech starts TB vaccine’s trials in adultsMarch 25, 2024 | marketwatch.comBio-Path Shares Close Lower After Withdrawing S-1March 13, 2024 | insidermonkey.comBioXcel Therapeutics, Inc. (NASDAQ:BTAI) Q4 2023 Earnings Call TranscriptMarch 10, 2024 | seekingalpha.comBio-Path Holdings Inc. (BPTH) Q4 2023 Earnings Call TranscriptMarch 10, 2024 | finance.yahoo.comBio-Path Holdings, Inc. (NASDAQ:BPTH) Q4 2023 Earnings Call TranscriptMarch 8, 2024 | msn.comWhy Bio-Path Holdings Shares Are Falling TodayMarch 8, 2024 | msn.comBio-Path files to sell 1.15M shares of common stock, warrantsMarch 8, 2024 | finanznachrichten.deBio-Path Holdings, Inc.: Bio-Path Holdings Reports Full Year 2023 Financial ResultsSee More Headlines Receive BPTH Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Bio-Path and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/08/2024Today4/23/2024Next Earnings (Estimated)5/10/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:BPTH CUSIPN/A CIK1133818 Webwww.biopathholdings.com Phone(832) 742-1357FaxN/AEmployees10Year Founded2007Price Target and Rating Average Stock Price Target$40.00 High Stock Price Target$40.00 Low Stock Price Target$40.00 Potential Upside/Downside+1,387.0%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($40.80) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-16,080,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-375.74% Return on Assets-248.63% Debt Debt-to-Equity RatioN/A Current Ratio1.60 Quick Ratio1.60 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.71 per share Price / Book3.79Miscellaneous Outstanding Shares680,000Free Float658,000Market Cap$1.83 million OptionableOptionable Beta0.36 Social Links Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report Key ExecutivesMr. Peter H. Nielsen MBA (Age 75)Co-Founder, Chairman of the Board, CEO, President, CFO & Treasurer Comp: $696.24kMr. Douglas P. Morris (Age 68)Co-Founder, Director of Investor Relations, Secretary & Director Comp: $73.74kMr. Michael Hickey M.B.A.VP of Clinical OperationsMr. Anthony PriceSenior Vice President of Finance, Accounting & AdministrationDr. Ana Tari Ashizawa Ph.D.MBA, Senior Vice President of Research, Development & Clinical DesignKey CompetitorsClearmind MedicineNASDAQ:CMNDHistogenNASDAQ:HSTOSalarius PharmaceuticalsNASDAQ:SLRXLucy Scientific DiscoveryNASDAQ:LSDINotable LabsNASDAQ:NTBLView All Competitors BPTH Stock Analysis - Frequently Asked Questions Should I buy or sell Bio-Path stock right now? 1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Bio-Path in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" BPTH shares. View BPTH analyst ratings or view top-rated stocks. What is Bio-Path's stock price target for 2024? 1 Wall Street analysts have issued 1 year price objectives for Bio-Path's shares. Their BPTH share price targets range from $40.00 to $40.00. On average, they expect the company's stock price to reach $40.00 in the next year. This suggests a possible upside of 1,389.8% from the stock's current price. View analysts price targets for BPTH or view top-rated stocks among Wall Street analysts. How have BPTH shares performed in 2024? Bio-Path's stock was trading at $9.26 on January 1st, 2024. Since then, BPTH stock has decreased by 71.0% and is now trading at $2.6850. View the best growth stocks for 2024 here. Are investors shorting Bio-Path? Bio-Path saw a increase in short interest in March. As of March 31st, there was short interest totaling 67,400 shares, an increase of 6.3% from the March 15th total of 63,400 shares. Based on an average daily trading volume, of 24,900 shares, the short-interest ratio is currently 2.7 days. Approximately 9.0% of the company's shares are sold short. View Bio-Path's Short Interest. When is Bio-Path's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Friday, May 10th 2024. View our BPTH earnings forecast. How were Bio-Path's earnings last quarter? Bio-Path Holdings, Inc. (NASDAQ:BPTH) announced its quarterly earnings results on Friday, March, 8th. The company reported ($5.40) EPS for the quarter, meeting analysts' consensus estimates of ($5.40). During the same period in the prior year, the company posted ($10.60) EPS. When did Bio-Path's stock split? Bio-Path's stock reverse split on the morning of Friday, February 23rd 2024. The 1-20 reverse split was announced on Friday, February 23rd 2024. The number of shares owned by shareholders was adjusted after the market closes on Friday, February 23rd 2024. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. What other stocks do shareholders of Bio-Path own? Based on aggregate information from My MarketBeat watchlists, some companies that other Bio-Path investors own include NVIDIA (NVDA), Palatin Technologies (PTN), Micron Technology (MU), Advanced Micro Devices (AMD), Amarin (AMRN), Trevena (TRVN), Energy Transfer (ET), Anavex Life Sciences (AVXL) and Biocept (BIOC). How do I buy shares of Bio-Path? Shares of BPTH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:BPTH) was last updated on 4/24/2024 by MarketBeat.com Staff From Our Partnerstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencySHOCKING Crypto Leak…Crypto 101 MediaDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsExposed: 10 CENT Crypto to Explode April 20th?True Market InsidersHow to camouflage a factory of 53,000 workersStansberry ResearchDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill PublishingThe #1 Crypto for 2024InvestorPlaceMan Who Predicted 2008: “This Will be Worse.”Altimetry Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Bio-Path Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
